Get a load of ZIF! Better delivery of cancer immunotherapy

February 11, 2021

Loading a cancer immunotherapy drug onto a metal organic framework improves both its delivery and its sustained release for treating leukemia. Furthermore, coating the drug-loaded framework with a cancer cell membrane improves targeted delivery to solid tumors. These findings could lead to safer and more reliable cancer immunotherapies.

"We believe our findings are quite significant because they show that the undesirable side effects of immunotherapy can be modulated by choosing the right delivery vehicle," says KAUST chemist Niveen Khashab. "They also show that targeted delivery can be realistically established through proper surface functionalization."

Cancer immunotherapy involves using drugs that modulate the immune system to make it more effective in attacking tumors. Nivolumab is one such drug, which counteracts a cancer immune evasion strategy that involves expressing PD-L1 molecules that deactivate T cells by blocking the PD-1 molecules on their surfaces.

Yet nivolumab, like other "immune checkpoint inhibitors", can cause immune-related adverse effects, where excessive T cell activation leads to an immune response against the recipient's organs. Scientists are looking for ways to improve the delivery of antibodies like nivolumab so that their release is slow, sustained and targeted, with minimal adverse effects.

Khashab's group worked with a metal organic framework called zeolitic imidazolate (ZIF-8), a crystalline solid formed of zinc ion subunits attached to organic methylimidazole. "ZIF-8 nanoparticles have shown great potential in cancer drug delivery in the last few years," says Somayah Qutub, a Ph.D. student in Khashab's group. "They are composed of zinc ions and imidazole, which are naturally found in the body." This makes the biocompatible, biodegradable and highly porous nature of ZIF-8 ideal for the safe loading and delivery of drugs like nivolumab.

Khashab's team loaded nivolumab onto ZIF-8 and tested its effects on leukemia cells. They found that the antibody was slowly released from the ZIF-8 framework when in proximity to a slightly acidic tumor microenvironment. This process prevents the T cells from being deactivated by cancerous cells so that they can attack the leukemia cells.

The team also tested the system for delivering the antibody to solid tumors both in Petri dish experiments and in mice. They encapsulated nivolumab-loaded ZIF-8 with the membrane of the cancer cells that were being targeted. This led to the accurate delivery of the system to the tumor, followed by slow and sustained drug release. Importantly, the mice showed negligible toxicity from the drug, which significantly inhibited tumor growth and prolonged survival.

"Our next step is to improve this system," says Qutub. "We are combining immunotherapy drugs with other anti-cancer modalities to have a synergic effect. We are also working on optimizing our cancer cell membrane coating with other materials so that the system can be easily reproducible, scalable and compatible with biopharmaceutical industry standards."
-end-


King Abdullah University of Science & Technology (KAUST)

Related Immunotherapy Articles from Brightsurf:

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Taking the itch out of cancer immunotherapy
Researchers from the University of Tsukuba have determined that PD-1 expression on CD8 T cells is the biological pathway that leads to psoriasis-like dermatitis, an unfavorable side effect of cancer immunotherapy with PD-1 inhibitors.

Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

New immunotherapy to beat cancer
Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.

New hydrogels for T-cell growth to be used in cancer immunotherapy
A team with the participation of researchers from the Spanish National Research Council (CSIC) has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A blood test could predict who benefits from immunotherapy
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

Read More: Immunotherapy News and Immunotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.